Experience With Ceftolozane-Tazobactam for the Treatment of Serious
Ceftolozane-tazobactam
Pseudomonas aeruginosa
Saudi Arabia
carbapenem-resistant
Journal
Infectious diseases
ISSN: 1178-6337
Titre abrégé: Infect Dis (Auckl)
Pays: United States
ID NLM: 101603964
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
01
2020
accepted:
21
01
2020
entrez:
29
2
2020
pubmed:
29
2
2020
medline:
29
2
2020
Statut:
epublish
Résumé
Multidrug-resistant A single-center retrospective observational study between January 2017 and December 2018 for patients who had been diagnosed with carbapenem-resistant A total of 19 patients fit the inclusion criteria, with a median age was 57 years, and 53% were female. The types of infections were nosocomial pneumonia, acute bacterial skin, and skin structure infections; complicated intra-abdominal infections; and central line-associated bloodstream infections. All of the isolates were resistant to both meropenem and imipenem. The duration of therapy was variable (average of 14 days). At day 14 of starting ceftolozane-tazobactam, 18 of 19 patients had a resolution of signs and symptoms of the infection. Only 14 of 19 patients (74%) had proven microbiological eradication observed at the end of therapy. During therapy, there was no adverse event secondary to ceftolozane-tazobactam, and no Multidrug-resistant
Identifiants
pubmed: 32110036
doi: 10.1177/1178633720905977
pii: 10.1177_1178633720905977
pmc: PMC7016308
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1178633720905977Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Clin Infect Dis. 2016 Jul 15;63(2):234-41
pubmed: 27098166
Drugs. 2014 Jan;74(1):31-51
pubmed: 24352909
Lancet Infect Dis. 2008 Mar;8(3):159-66
pubmed: 18291338
Clin Infect Dis. 2017 Jul 1;65(1):158-161
pubmed: 28329350
Int J Antimicrob Agents. 2019 Apr;53(4):408-415
pubmed: 30415002
J Pharmacokinet Pharmacodyn. 2017 Apr;44(2):113-132
pubmed: 28161807
Antimicrob Agents Chemother. 2018 Feb 23;62(3):
pubmed: 29263073
Ann Pharmacother. 2015 Jan;49(1):86-98
pubmed: 25361682
Clin Microbiol Infect. 2017 Oct;23(10):704-712
pubmed: 28893690
J Microbiol Immunol Infect. 2011 Apr;44(2):125-30
pubmed: 21439515
Clin Infect Dis. 2017 Jul 1;65(1):110-120
pubmed: 29017262
Open Forum Infect Dis. 2018 Oct 31;5(11):ofy280
pubmed: 30488041
Int J Antimicrob Agents. 2007 Oct;30(4):315-9
pubmed: 17631984
J Antimicrob Chemother. 2007 Aug;60(2):247-57
pubmed: 17562680